NCT01962207View on ClinicalTrials.gov

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

PHASE3CompletedINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2018

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Meningococcal vaccine GSK134612

One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm

Trial Locations (9)

20520

Tampereen yliopisto/ Turun rokotetutkimusklinikka, Turku

28100

Tampereen yliopisto/ Porin rokotetutkimusklinikka, Pori

33100

Tampere Vaccine Research Clinic, Tampere

90220

Tampereen yliopisto/ Oulun rokotetutkimusklinikka, Oulu

02230

Espoo Vaccine Research Clinic, Espoo

00100

South Helsinki Vaccine Research Clinic, Helsinki

00930

Helsinki East Vaccine Research Clinic, Helsinki

04400

Jarvenpaa Vaccine Research Clinic, Järvenpää

01300

Tampereen yliopisto/ Ita-Vantaan rokotetutkimusklinikka, Vantaa

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01962207 - The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination | Biotech Hunter | Biotech Hunter